Echo Therapeutics Inc  

(Public, NASDAQ:ECTE)   Watch this stock  
Find more results for ECTE
-0.18 (-7.13%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.41 - 2.62
52 week 0.39 - 3.47
Open 2.62
Vol / Avg. 52,460.00/64,196.00
Mkt cap 30.44M
P/E     -
Div/yield     -
EPS -1.01
Shares 12.63M
Beta 1.07
Inst. own 24%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -28804.71% -69084.78%
Operating margin -15245.16% -71146.63%
EBITD margin - -69727.79%
Return on average assets -142.33% -88.46%
Return on average equity -166.83% -131.60%
Employees 57 -
CDP Score - -


99 Wood Ave S Ste 302
ISELIN, NJ 08830-2715
United States - Map
+1-215-7174100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Echo Therapeutics Inc. is a medical device company with its focus on skin permeation technology. The Company has developed its needle-free skin preparation device, the Prelude SkinPrep System, which is used in the delivery of topical pharmaceuticals. The Company has also developed Symphony CGM System, which is a needle-free, wireless, continuous glucose monitoring system that is designed to provide blood glucose data. Symphony incorporates Prelude, the company�s skin permeation device, a transdermal sensor, a wireless transceiver and a data display technology. The Company completed Prelude SkinPrep System, a 510(k) equivalency study, to determine the efficacy of Prelude in enhancing the onset of the effectiveness of 4% lidocaine cream. Durhalieve is the Company's topical AzoneTS reformulation of triamcinolone acetonide, which is used for the treatment of corticosteroid-responsive dermatoses. Durhalieve has completed Phase III clinical trials.

Officers and directors

Robert F. Doman Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Scott Wayne Hollander President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Alan W. Schoenbart CPA Chief Financial Officer
Age: 52
Bio & Compensation  - Reuters
Michael M. Goldberg M.D. Director
Age: 56
Bio & Compensation  - Reuters
Shepard M. Goldberg Director
Age: 55
Bio & Compensation  - Reuters